 HOUSTON, Nov. 04, 2021 GLOBE NEWSWIRE -- Bio-Path Holdings, Inc., NASDAQ: BPTH, a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming poster presentation at the 2021 American Society of Hematology ASH Annual Meeting and Exposition, taking place from December 11-14, 2021 in Atlanta, GA. In addition, ASH abstracts will appear in the November supplemental issue of Blood. 